Table 2—

Clinical characteristics and fasting metabolic profile in subjects with or without retinopathy in association with presence of PSN, defined as pathological monofilament or VPT ≥25 V

No retinopathy
Retinopathy
P*Ps
PSN−PSN+PPSN−PSN+P
n58271916
% male48810.0045869NSNSNS
Age (years)59.1 ± 7.665.3 ± 5.30.000160.5 ± 8.163.8 ± 5.6NS0.03NS
Diabetes duration (years)5.3 ± 4.37.1 ± 5.9NS8.8 ± 6.110.8 ± 7.1NS0.0010.07
BMI (kg/m2))30.3 ± 4.927.9 ± 4.10.0329.5 ± 4.729.8 ± 5.0NSNSNS
Waist index1.16 ± 0.141.11 ± 0.120.11.13 ± 0.161.15 ± 0.14NSNSNS
hsCRP (mg/l)2.60 ± 2.453.38 ± 4.02NS3.08 ± 2.462.55 ± 2.08NSNSNS
Systolic blood pressure (mmHg)145 ± 18150 ± 17NS149 ± 21154 ± 20NSNSNS
Diastolic blood pressure (mmHg)84 ± 983 ± 10NS79 ± 887 ± 130.07NSNS
Fasting plasma glucose (mmol/l)8.8 ± 2.88.9 ± 3.8NS8.5 ± 2.410.2 ± 2.4<0.050.050.1
A1C (%)6.3 ± 1.36.2 ± 1.2NS6.7 ± 1.36.9 ± 1.0NS0.060.07
IGF-1 (μg/l)130 ± 64116 ± 55NS133 ± 59138 ± 63NSNSNS
IGF-1 SD−0.92 ± 1.71−1.03 ± 2.13NS−0.58 ± 1.62−0.35 ± 1.62NSNSNS
IGFBP-1 (μg/l)18 ± 1534 ± 340.0419 ± 1829 ± 180.020.004NS
IGFBP-3 (μg/l)3,670 ± 1,0393,190 ± 8610.043,724 ± 1,2533,314 ± 1,518NSNSNS
IGF-1–to–IGFBP-1 ratio12.5 ± 11.213.0 ± 20.80.0413.2 ± 12.36.4 ± 5.30.03<0.05NS
Cholesterol (mmol/l)5.04 ± 1.015.13 ± 1.40NS4.93 ± 1.264.80 ± 0.86NSNSNS
HDL cholesterol (mmol/l)1.23 ± 0.351.15 ± 0.36NS1.23 ± 0.351.16 ± 0.44NSNSNS
Triglycerides (mmol/l)1.85 ± 1.182.05 ± 1.92NS1.57 ± 0.681.87 ± 1.33NSNSNS
Cystatin C (mg/l)0.68 ± 0.230.88 ± 0.420.070.80 ± 0.240.87 ± 0.31NS<0.05NS
Creatinine (μmol/l)74 ± 1586 ± 220.00473 ± 1677 ± 23NSNS0.1
UAlb (mg/l)11 ± 1136 ± 670.06102 ± 251463 ± 789NS0.0040.1
VPT (V)16.1 ± 5.130.2 ± 7.817.8 ± 3.335.0 ± 7.80.05
  • Data are means ± SD unless otherwise indicated. P refers to one-way ANOVA. IGF-1 SD is the score as calculated from healthy subjects.

  • *

    * No retinopathy/PSN− vs. retinopathy/PSN+.

  • No retinopathy/PSN+ vs. retinopathy/PSN+.